CEL-SCI Corporation

CVM

US1508376076

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
1.21 ^USD	+10.00%		+4.31%	-55.51%

07-01	CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index	CI
07-01	CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index	CI

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index

July 30, 2024

Latest news about CEL-SCI Corporation

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index	06-30	CI
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index	06-30	CI
CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population	06-20	CI
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	05-08	MT
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	05-08	CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	05-08	CI
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	04-23	CI
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
Cel-Sci Closes $7.8 Million Share Offering	02-13	MT
Health Care Slips on Rotation to High-Risk Sectors -- Health Care Roundup	02-09	DJ
Cel-Sci Prices $7.8 Million Public Offering of Common Shares	02-09	MT
CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	02-06	CI
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	01-31	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	01-31	MT
Cel-Sci Receives Pediatric Requirements Waiver for Multikine From European Medicines Agency	01-31	MT
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	12-28	DJ
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	12-21	CI
Cel-Sci Closes $5 Million Common Stock Offering	11-20	MT
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals	24/10/23	CI
Sector Update: Health Care Stocks Softer Late Afternoon	23/10/23	MT
Sector Update: Health Care	23/10/23	MT
Top Midday Gainers	23/10/23	MT
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain	23/10/23	CI
Transcript : CEL-SCI Corporation - Special Call	22/10/23

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.21 USD

Average target price

6.6 USD

Spread / Average Target

+445.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CEL-SCI CORPORATION	-55.51%	65.53M
CSL LIMITED	+3.11%	97.7B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-12.80%	32.85B
UCB	+81.56%	29.33B
BIOMARIN PHARMACEUTICAL INC.	-15.53%	15.47B
INCYTE CORPORATION	-8.70%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.51B
ALTEOGEN INC.	+183.25%	10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.41%	8.97B

Biopharmaceuticals